// App-Quantinova.ai

: Interim Results from an Ongoing Phase 2 Multicenter Study of Tazemetostat, an EZH2 Inhibitor, in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

Researchers

Presenter

  • Vincent Ribrag

Principal Investigators

  • Pamela McKay

  • Gilles Andre Salles

  • Connie Lee Batlevi

  • Anna Schmitt

  • Herve Tilly

  • Guillaume Cartron

  • Catherine Thieblemont

  • Christophe Fruchart

  • John G. Gribben

  • Thierry Lamy

  • Steven Le Gouill

  • Reda Bouabdallah

  • Michael Dickinson

  • Stephen Opat

  • Deyaa Adib

  • Stephen J Blakemore

  • John Larus

  • Peter Johnson

Medical Centers

  • Gustave Roussy, Villejuif, France

  • Hematologie, Centre Hospitalier Universitaire, Universite de Lille, EA GRIIOT, Lille, France

  • Department of Haematology,Beatson West of Scotland Cancer Centre,Glasgow,United Kingdom

  • Hospices Civils de Lyon, Universite Lyon-1, Lyon, France

  • Lymphoma Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY

  • Institut Bergonie, Bordeaux, France

  • Service d'hématologie, Centre de Lutte Contre le Cancer Henri Becquerel, Rouen, France

  • Department of Gastroenterology, CHU de Montpellier, Montpellier, France

  • Aphp Saint-Louis Hospital, Paris, France

  • Centre Francois Baclesse, Caen, France

  • Barts Cancer Institute, Queen Mary University of London, London, United Kingdom

  • CHU Rennes, Rennes, France

  • Universite Nantes, Nantes, France

  • Institut Paoli-Calmettes, Marseille, France

  • Peter MacCallum Cancer Center, Royal Melbourne Hospital, and University of Melbourne ,Melbourne,Australia

  • Deakin University, Melbourne, Australia

  • Epizyme, Cambridge, MA

  • Cancer Sciences, University of Southampton, Southampton, United Kingdom

Locations

  • France

  • United Kingdom

  • United States

  • Australia

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Diffuse large B-cell lymphoma

Biomarkers

  • Enhancer of zeste homolog 2

Drug/Treatment

  • Tazemetostat

  • Prednisolone

  • EZH2

Outcome

  • N/A

Study Design

  • Multicenteric

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved